🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to scientists.

An International Public Health Issue

The sexually transmitted infection are on the rise worldwide, with figures suggesting more than 82 million instances annually. Especially elevated rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely step in the reality of increasing worldwide cases, the spread of superbugs and the very limited treatment choices at this time.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program found that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers hope that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, was also approved in close succession. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This approval marks a huge turning point in the management of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Data and Global Access

Based on results detailed in a prominent scientific publication, the new drug eradicated more than 90% of cases of the STI. This establishes an comparable level with the typical regimen, which uses two antibiotics. The research involved nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians directly involved have voiced optimism. The availability of a easy-to-administer therapy such as this is described as a "game-changer" for managing the epidemic. This is viewed as vital to alleviate the strain of the infection for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.